A double - blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of <font color="blue">skeletal_2</font> <font color="blue">myoblast_2</font> <font color="blue">implantation_2</font> <font color="blue">by_1</font> <font color="blue">catheter_2</font> <font color="blue">delivery_2</font> in patients with chronic heart failure after myocardial infarction . 
<br>
<br> BACKGROUND We sought to determine the safety and preliminary efficacy of <font color="blue">transcatheter_1</font> <font color="blue">intramyocardial_1</font> <font color="blue">administration_1</font> <font color="blue">of_1</font> <font color="blue">myoblasts_2</font> in patients with heart failure ( HF ) . 
<br> METHODS MARVEL is a randomized <font color="blue">placebo_1</font> <font color="blue">-_1</font> <font color="blue">controlled_1</font> <font color="blue">trial_1</font> <font color="blue">of_1</font> <font color="blue">image_1</font> <font color="blue">-_1</font> <font color="blue">guided_1</font> <font color="blue">,_1</font> <font color="blue">catheter_2</font> <font color="blue">-_2</font> <font color="blue">based_2</font> <font color="blue">intramyocardial_2</font> <font color="blue">injection_2</font> <font color="blue">of_2</font> <font color="blue">placebo_4</font> <font color="blue">or_3</font> <font color="blue">myoblasts_5</font> <font color="blue">(_1</font> <font color="blue">400_1</font> <font color="blue">or_1</font> <font color="blue">800_1</font> <font color="blue">million_1</font> <font color="blue">)_1</font> in patients with class II to IV HF and ejection fraction < 35% . Primary end points were frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) . Of 330 patients intended for enrollment , 23 were randomized ( MARVEL-1 ) before stopping the study for financial reasons . 
<br> RESULTS At 6 months , similar numbers of events occurred in each group : 8 ( <font color="blue">placebo_1</font> <font color="blue">)_1</font> , 7 ( low dose ) , and 8 ( high dose ) , without deaths . Ventricular tachycardia responsive to amiodarone was more frequent in <font color="blue">myoblast_1</font> <font color="blue">-_1</font> treated patients : 1 ( <font color="blue">placebo_1</font> <font color="blue">)_1</font> , 3 ( low dose ) , and 4 ( high dose ) . A trend toward improvement in functional capacity was noted in <font color="blue">myoblast_1</font> <font color="blue">-_1</font> treated groups ( Î”6-minute walk test of -3.6 vs + 95.6 vs + 85.5 m [ <font color="blue">placebo_1</font> vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores . 
<br> CONCLUSIONS In HF patients with chronic postinfarction cardiomyopathy , transcatheter administration of <font color="blue">myoblasts_1</font> in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits . Ventricular tachycardia may be provoked by <font color="blue">myoblast_1</font> injection but appears to be a transient and treatable problem . A large - scale outcome trial of <font color="blue">myoblast_1</font> administration in HF patients with postinfarction cardiomyopathy is feasible and warranted .